Specialties

Genetic and phenotypic risk model predicts MS

Presented By

Ms Alyks Linerud, Brigham Young University, UT, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:38

Novel AI algorithm better identifies risk factors of MS

Presented By

Dr Zongqi Xia, University of Pittsburgh, PA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:36

Paramagnetic rim lesions predict effectiveness of tolebrutinib

Presented By

Dr Jiwon Oh, University of Toronto, Canada

Trial

HERCULES, GEMINI

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:34

Atypical and radiological-only presentations often meet 2024 MS criteria

Presented By

Ms Alexandra Scharf, Cleveland Clinic, OH, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:29

Treatment with cladribine tablets: real-world insights

Presented By

Mr Gerard Harty, Merck KGaA, Germany

Trial

CLADRISE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:27

Favourable effectiveness and persistence of cladribine versus other oral DMTs

Presented By

Prof. Helmut Butzkueven, Monash University, Australia

Trial

GLIMPSE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:26

Ofatumumab: good initial adherence and treatment satisfaction

Presented By

Dr Anneke van der Walt, Monash University, Australia

Trial

EAFToS

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:24

MS activity remains low on long-term fenebrutinib

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Trial

Phase 2, FENopta

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:22

Higher-dosed ocrelizumab associated with less disability accrual

Presented By

Dr Robert Bermel, Cleveland Clinic, OH, USA

Trial

Phase 3, OPERA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:21

Ocrelizumab significantly reduces new/enlarging cortical lesions

Presented By

Prof. Michael Dwyer, University at Buffalo, NY, USA

Trial

Phase 3, ORATORIO

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:19

Discontinuing therapy has few risks in patients with MS over 60 years

Presented By

Prof. John Corboy, University of Colorado, CO, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:17

Comorbidity burden associated with risk of adverse events

Presented By

Prof. Amber Salter, UT Southwestern Medical Center, TX, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:15

Update on safety profile of cladribine tablets yields positive results

Presented By

Prof. Thomas Leist, Jefferson University, PA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:14

Safety of 30-minute ublituximab infusions confirmed

Presented By

Dr John Foley, Rocky Mountain Multiple Sclerosis Center, UT, USA

Trial

ENHANCE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:12

Orelabrutinib highly effective in relapsing-remitting MS, based on MRI results

Presented By

Prof. Yan Xu, Peking Union Medical College Hospital, China

Trial

Phase 2

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:08

Immunomodulatory potential of ketogenic diet in MS confirmed

Presented By

Dr Michael Kornberg, Johns Hopkins University, MD, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:06

A pre-relapse immune signature implicates EBV reactivation in MS relapse

Presented By

Dr Devin King, Brigham and Women’s Hospital, MA, USA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:03

Meet the Trialist: Dr Jiwon Oh

Expert

Dr Jiwon Oh, St Michael’s Hospital, University of Toronto, Canada

Conference

ACTRIMS 2025

5 March 2025 10:59

The locus coeruleus is involved in processing pain in migraine

Presented By

Dr Veronica Munday, King’s College London, UK

Conference

EHC 2024

Type

News article

6 January 2025 11:47

Cortical spreading depolarisation impacts glymphatic flow, with consequences for migraine aura

Presented By

Ms Zi-Rou Jiang, National Yang Ming Chiao Tung University, Taiwan

Conference

EHC 2024

Type

News article

6 January 2025 11:46

AI can enhance migraine diagnosis using easy-to-measure clinical data

Presented By

Dr Antonios Danelakis, Norwegian University of Science and Technology, Norway

Conference

EHC 2024

Type

News article

6 January 2025 11:43

MRI analyses suggest that migraine is not associated with altered brain white matter

Presented By

Dr Cédric Gollion, University Hospital Centre of Toulouse, France

Trial

REFORM

Conference

EHC 2024

Type

News article

6 January 2025 11:39

More education on migraine features is needed

Presented By

Dr Lucas Overeem, Charité University Medicine Berlin, Germany

Conference

EHC 2024

Type

News article

6 January 2025 11:37

PACAP-targeting therapies: a future option for migraine?

Presented By

Dr Zixuan Alice Zhuang, University of Copenhagen, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:36

Rapid complete responses with atogepant

Presented By

Dr Andreas Gantenbein, Zurzach Care, Switzerland

Trial

Phase 3, ADVANCE, ELEVATE, PROGRESS

Conference

EHC 2024

Type

News article

6 January 2025 11:35

Cabergoline is a potential add-on treatment option in patients with migraine

Presented By

Dr Astrid Hjelholt, Aarhus University Hospital, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:32

Nitroglycerin-induced migraine targetable by different agents

Presented By

Dr Charlotte Ernstsen Lauritzen, H. Lundbeck A/S, Denmark

Conference

EHC 2024

Type

News article

6 January 2025 11:31

Rimegepant reduces migraine symptoms through 1 year of treatment

Presented By

Dr Shengyuan Yu, PLA General Hospital, China

Trial

Phase 2

Conference

EHC 2024

Type

News article

6 January 2025 11:29

Fremanezumab is a treatment option for paediatric patients with episodic migraine

Presented By

Prof. Patricia Pozo-Rosich, Vall d’Hebron Institute of Research, Spain

Trial

Phase 3, SPACE-EM

Conference

EHC 2024

Type

News article

6 January 2025 11:27

What brain changes are associated with fremanezumab treatment success?

Presented By

Prof. Ángel Guerrero, University of Valladolid, Spain

Trial

FreMRI

Conference

EHC 2024

Type

News article

6 January 2025 11:25

Low discontinuation rates with preventative galcanezumab in a real-world setting

Presented By

Dr Sait Ashina, Harvard Medical School, MA, USA

Trial

TRIUMPH

Conference

EHC 2024

Type

News article

6 January 2025 11:23

Biofeedback training can reduce affected days in episodic migraine

Presented By

Dr Amalie Christine Poole, Norwegian University of Science and Technology, Norway

Trial

BioCer

Conference

EHC 2024

Type

News article

6 January 2025 11:20

Virtual reality interventions can reduce pain perception of chronic headache

Presented By

Prof. Sara Bottiroli, University of Pavia, Pavia, Italy

Conference

EHC 2024

Type

News article

6 January 2025 11:18

Can predisposing factors be targeted to reduce new migraine incidence?

Presented By

Ms Maria Terhart, Charité University Medicine Berlin, Germany

Conference

EHC 2024

Type

News article

6 January 2025 11:15

Active migraine comes at a high cost in Spain

Presented By

Dr Margarita Sánchez del Río, Clinica Universidad de Navarra, Spain

Conference

EHC 2024

Type

News article

6 January 2025 11:13

Many patients, including non-responders, prefer triptans over non-headache-specific medication

Presented By

Dr Arne Hostens, Free University of Brussels, Belgium

Conference

EHC 2024

Type

News article

6 January 2025 11:12

DPP-4 is better target to lower migraine rates in patients with type 2 diabetes

Presented By

Dr Chen Ting-Chuan, Taichung Veterans General Hospital, Taiwan

Conference

EHC 2024

Type

News article

6 January 2025 11:10

CGRP antagonists show different potencies for CGRP isoforms in different vascular compartments

Presented By

Ms Deirdre Boucherie, Erasmus University Medical Centre Rotterdam, the Netherlands

Conference

EHC 2024

Type

News article

6 January 2025 11:08

Revised McDonald criteria allow earlier and more precise MS diagnosis

Presented By

Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:52

Approaches to RIS and MS converge

Presented By

Prof. Christine Lebrun-Frénay, Centre Hospitalier Universitaire de Nice, France

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:50

AI versus clinicians: who diagnoses MS faster and better?

Presented By

Ms Mahi Patel, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:47

Blood markers predict MS progression

Presented By

Dr Ahmed Abdelhak, University of California San Francisco, CA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:46

Gut microbiota modulate inflammation and cortical damage

Presented By

Dr Federico Montini, Brigham and Women's Hospital, MA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:43

Risk factors and importance of persistent PIRA

Presented By

Dr Chao Zhu, Monash University, Australia

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:39

Vitamin D supplementation in progressive MS should be medically supervised

Presented By

Dr Michaela Haindl, Medical University of Graz, Austria

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:38

Encouraging real-world results of AHSCT to treat aggressive MS

Presented By

Prof. Paolo Muraro, London Bridge Hospital, UK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:35

CAR T-cell therapy in MS: in its infancy but highly anticipated

Presented By

Prof. Frauke Zipp, Johannes Gutenberg University Mainz, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:33

B cell-tailored dosing of ocrelizumab shows good results

Presented By

Ms Laura Hogenboom, Amsterdam University Medical Center, the Netherlands

Trial

BLOOMS

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:28

Risk associated with discontinuing therapy depends on specific drug

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:26

First-line moderate-efficacy DMTs show similar efficacy

Presented By

Dr Clara López-Caneda, Hospital Alvaro Cunqueiro, Spain

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:23

Tolebrutinib slows disability worsening in relapsing MS

Presented By

Dr Jiwon Oh, St. Michael's Hospital, Canada

Trial

Phase 3, GEMINI 1, GEMINI 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:21

Frexalimab shows favourable safety and efficacy in OLE

Presented By

Prof. Gavin Giovannoni, Queen Mary University of London, UK

Trial

Phase 2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:17

Good safety of ozanimod over up to 8 years of treatment

Presented By

Prof. Krzysztof Selmaj, University of Warmia and Mazury, Poland

Trial

DAYBREAK

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:16

Tolebrutinib slows disability in non-relapsing SPMS

Presented By

Prof. Robert Fox, Cleveland Clinic, OH, USA

Trial

Phase 3, HERCULES

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:13

High-dose simvastatin does not slow disability progression in SPMS

Presented By

Dr Jeremy Chataway, University College London, UK

Trial

Phase 3, MS-STAT2

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:11

High genetic burden for depression associated with MS disease activity

Presented By

Dr Kaarina Kowalec, University of Manitoba, Canada

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:06

More comorbidity is associated with worse clinical outcomes in MS

Presented By

Dr Amber Salter, UT Southwestern, TX, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:05

Transfer of ocrelizumab into breastmilk is negligible

Presented By

Dr Riley Bove, University of California San Francisco, CA, USA

Trial

Phase 4, SOPRANINO

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:03

STEEER-AF: Shockingly low adherence to ESC atrial fibrillation guidelines

Presented By

Prof. Dipak Kotecha, University of Birmingham, UK

Trial

STEEER-AF

Conference

ESC 2024

Type

Peer-reviewed article

7 November 2024 11:10

Vagal nerve stimulation for the reduction of cognitive impairment in Alzheimer’s disease

Presented By

Dr Adam Broncel, Neuromedical, Poland

Conference

EAN 2024

Type

News article

25 July 2024 11:07

Under investigation: Opioid use and the risk for dementia

Presented By

Dr Nelsan Pourhadi, Copenhagen University Hospital Rigshospitalet, Denmark

Conference

EAN 2024

Type

News article

25 July 2024 10:45

High risk for recurrent vascular events in young stroke patients

Presented By

Dr Jenna Broman, University of Helsinki, Finland

Conference

EAN 2024

Type

News article

25 July 2024 10:28

Anticoagulation or antiplatelet as secondary prevention for cancer-related strokes?

Presented By

Dr Moritz Kielkopf, University of Bern, Switzerland

Conference

EAN 2024

Type

News article

25 July 2024 10:26

Treatment escalation and de-escalation in late-onset MS

Presented By

Prof. Fredrik Piehl, Karolinska University Hospital, Sweden

Conference

EAN 2024

Type

News article

25 July 2024 10:22

How different are late onset and adult onset MS really?

Presented By

Dr Celine Louapre, Sorbonne University, France

Conference

EAN 2024

Type

News article

25 July 2024 10:17

Intensive BP intervention reduces risk of dementia 

Presented By

Dr Jiang He, Tulane University, USA

Conference

AHA 2023

Type

Peer-reviewed article

29 January 2024 14:01

Breakthrough in Predicting MS Progression Through Genetic Testing

Expert

Prof. Sergio Baranzini, University of California San Francisco, CA, USA

4 December 2023 14:52

Retinal OCT markers hold promise for early MS diagnosis

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:13

Early intensive treatment enhances long-term clinical outcomes

Presented By

Dr Pietro Iaffaldano, University of Bari, Italy

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:12

χ-separation can assess the effects of tissue destruction in early MS lesions

Presented By

Dr Jannis Müller, University of Basel, Switzerland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:12

Anti-CD40L antibody safe and effective in a phase 2 study

Trial

Phase 2

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:11

High sGFAP levels are associated with disease progression, independent of NfL or relapse activity

Presented By

Dr Pascal Benkert, University Hospital Basel, Switzerland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:11

Oral glycolipid shows promise in the treatment of MS, especially SPMS

Presented By

Dr Tomoko Okamoto, National Center Hospital, Tokyo, Japan

Trial

Phase 2

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Prioritising high efficacy therapies in children with MS

Presented By

Dr Nail Benallegue, Nantes University, France

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

New insights into the contribution of EBV to MS pathogenesis

Presented By

Prof. Thomas Berger, Medical University of Vienna, Austria

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Early initiation of highly active treatment associated with a lower risk of SPMS

Presented By

Dr Christine Lebrun-Frenay, CHU de Nice, France

Trial

SPAM

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Broad rim lesions correlate with a rapidly progressive MS phenotype

Presented By

Dr Jussi Lehto, University of Turku, Finland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:10

Progressive brain tissue loss precedes the onset of clinical MS by years

Presented By

Dr Christina Azevedo, University of Southern California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

COVID-19 infection associated with higher MS relapse rate

Presented By

Mr David Levitz, Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Rate of grey matter brain atrophy accelerates after menopause

Presented By

Dr Alyssa Nylander, University of California, CA, USA

Trial

EPIC

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Omega-3 polyunsaturated fatty acids associated with lower risk of MS activity

Presented By

Dr Vinicius Schoeps, University of California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients

Presented By

Dr Yi Chao Foong, Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Smouldering inflammation detectable even in the earliest stages of MS

Presented By

Dr Markus Matilainen, University of Turku, Finland

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Fenebrutinib shows rapid reduction of new Gd+ T1 lesions

Presented By

Prof. Amit Bar-Or, University of Pennsylvania, PA, USA

Trial

Phase 2, FENopta

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Sickness absence rate increases years before clinical onset of MS

Presented By

Dr Ali Manouchehrinia, Karolinska University, Sweden

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Understanding what an MS cure means and what it takes

Presented By

Prof. Stephen Hauser, University of California, CA, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Telerehabilitation effective in improving MS symptoms in patients with moderate disability

Presented By

Dr Maria Petracca, Sapienza University of Rome, Italy

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Challenges of de-escalation versus discontinuation of highly effective DMTs in older MS patients

Presented By

Prof. Vincent Van Pesch, UCLouvain, Belgium

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Real-world data supports ocrelizumab prior to conception

Presented By

Dr Wei Yeh, Alfred Health and Monash University, Australia

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:07

Nightmares during childhood linked to cognitive decline later in life

Presented By

Dr Abidemi Otaiku, University of Birmingham, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:55

Which patients can initially be treated with platform DMT?

Presented By

Dr Ilaria Addazio, University of Florence, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:44

Retinal layer thickness predicts disability accumulation in early RMS

Presented By

Prof. Gabriel Bsteh, Medical University of Vienna, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:38

Withdrawing DMF in early pregnancy does not increase relapse risk in pregnant patients with MS

Presented By

Prof. Doriana Landi, University of Rome Tor Vergata, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:12

Immunosenescence and MS: relevance to immunopathogenesis and treatment

Presented By

Prof. Monika Adamczyk-Sowa, Medical University of Silesia, Poland

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:04

GLP-1 agonists induce weight loss and alleviate headache in idiopathic intracranial hypertension

Presented By

Dr Nik Krajnc, Medical University of Vienna, Austria

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 11:00

80% of patients reverse from chronic to episodic migraine on anti-CGRP antibodies

Presented By

Dr Gabriella Egeo, IRCCS San Raffaele, Italy

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:52

Towards cell biology of Alzheimer’s disease

Presented By

Prof. Thomas C. Südhof, Stanford Medicine, CA, USA

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:35

Intensive BP reduction associated with smaller haematoma

Presented By

Prof. Qi Li, Chongqing Medical University, China

Trial

Phase 3, ATACH-2

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 10:26

Contribution of genomics and genetics to personalised medicine

Presented By

Prof. Nicholas Wood, University College London, UK

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 09:56

How big data can boost care for neurodegenerative disorders

Presented By

Prof. Gunhild Waldemar, University of Copenhagen, Denmark

Conference

EAN 2023

Type

Peer-reviewed article

7 September 2023 09:46